AMINO ACID SEQUENCE OF ANTICANCER HUMAN MONOCLONAL ANTIBODY AND DNA BASE SEQUENCE CODING FOR THE SAME

PROBLEM TO BE SOLVED: To obtain the subject new antibody fragment containing a hypervariable region CDR3 having a specific amino acid sequence, having binding property to mouse anti-idio type antibody against human immunoglobulin which is specific to a human cancer cell antigen and suppressing proli...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HAGIWARA HIDEAKI, MIYAHARA JUNICHI, AOZUKA YASUYUKI
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA DERIVATIVES THEREOF ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS SUGARS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PROBLEM TO BE SOLVED: To obtain the subject new antibody fragment containing a hypervariable region CDR3 having a specific amino acid sequence, having binding property to mouse anti-idio type antibody against human immunoglobulin which is specific to a human cancer cell antigen and suppressing proliferation of human cancer cell. SOLUTION: This new immunoglobulin heavy chain variable region fragment contains a hypervariable region CDR3 having an amino acid sequence represented by formula I, further contains hypervariable region CDR1 having amino acid sequence represented by formula II and/or a hypervariable region CDR2 having an amino acid sequence represented by formula III. The fragment has a binding property to mouse anti-idio type antibody against human immunoglubulin which is specific to human cancer cell antigen and is useful as an anticancer agent, etc. The antibody fragment is obtained by fusing a peripheral blood lymphocyte of a cancer patient to which an anti-human cancer cell human monoclonal antibody is administered with a human lymphocyte, selecting a hybridoma producing antibody having binding property to anti-ideo type antibody of the monoclonal antibody and carrying out enzymatic treatment of an antibody produced by the hybridoma.